| Source: |
| Type: |
| Beta-Amyloid (Aβ): In Alzheimer’s disease, Aβ peptides tend to misfold and aggregate into oligomers and fibrils. |
| 3374- | QC, | Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis |
| - | Review, | Oral, | NA | - | Review, | AD, | NA |
| 6056- | RES, | SeNPs, | A comparative study of resveratrol and resveratrol-functional selenium nanoparticles: Inhibiting amyloid β aggregation and reactive oxygen species formation properties |
| - | Study, | AD, | NA |
| 6051- | RES, | SeNPs, | Chit, | Resveratrol-loaded selenium/chitosan nano-flowers alleviate glucolipid metabolism disorder-associated cognitive impairment in Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 6054- | RES, | SeNPs, | Oral Administration of Resveratrol-Selenium-Peptide Nanocomposites Alleviates Alzheimer's Disease-like Pathogenesis by Inhibiting Aβ Aggregation and Regulating Gut Microbiota |
| - | in-vivo, | AD, | NA |
| 3612- | RES, | Resveratrol in Alzheimer's disease: a review of pathophysiology and therapeutic potential |
| - | Review, | AD, | NA |
| 3613- | RES, | Resveratrol for Alzheimer's disease |
| - | Review, | AD, | NA |
| 3080- | RES, | Resveratrol: A miraculous natural compound for diseases treatment |
| - | Review, | Var, | NA |
| 3100- | RES, | Neuroprotective effects of resveratrol in Alzheimer disease pathology |
| - | Review, | AD, | NA |
| 3057- | RES, | The therapeutic effect of resveratrol: Focusing on the Nrf2 signaling pathway |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 4286- | RES, | Neuroprotective Properties of Resveratrol and Its Derivatives—Influence on Potential Mechanisms Leading to the Development of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4284- | RES, | Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex |
| - | in-vitro, | AD, | HEK293 | - | NA, | Stroke, | NA | - | in-vivo, | AD, | NA |
| 3729- | RF, | Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3730- | RF, | Transcranial electromagnetic treatment against Alzheimer's disease: why it has the potential to trump Alzheimer's disease drug development |
| - | Review, | AD, | NA |
| 3731- | RF, | Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice |
| - | in-vivo, | AD, | NA |
| 3732- | RF, | Electromagnetic treatment to old Alzheimer's mice reverses β-amyloid deposition, modifies cerebral blood flow, and provides selected cognitive benefit |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3738- | RF, | Electromagnetic Field Stimulation Therapy for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3743- | RF, | Repeated electromagnetic field stimulation lowers amyloid-β peptide levels in primary human mixed brain tissue cultures |
| - | in-vitro, | AD, | NA |
| 3461- | RF, | Electromagnetic Field Stimulation Therapy for Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3490- | RF, | Multidimensional insights into the repeated electromagnetic field stimulation and biosystems interaction in aging and age-related diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3616- | RosA, | Therapeutic effects of rosemary (Rosmarinus officinalis L.) and its active constituents on nervous system disorders |
| - | Review, | AD, | NA |
| 3619- | RosA, | Rosmarinic acid suppresses Alzheimer’s disease development by reducing amyloid β aggregation by increasing monoamine secretion |
| - | Review, | AD, | NA |
| 3620- | RosA, | Rosmarinus officinalis and Methylphenidate Exposure Improves Cognition and Depression and Regulates Anxiety-Like Behavior in AlCl3-Induced Mouse Model of Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3003- | RosA, | Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3028- | RosA, | Network pharmacology mechanism of Rosmarinus officinalis L.(Rosemary) to improve cell viability and reduces apoptosis in treating Alzheimer’s disease |
| - | in-vitro, | AD, | HT22 | - | in-vivo, | NA, | NA |
| 3937- | RT, | Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 3936- | RT, | Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroinflammation |
| - | in-vivo, | AD, | NA |
| 3935- | RT, | Sodium rutin ameliorates Alzheimer's disease-like pathology by enhancing microglial amyloid-β clearance |
| - | in-vivo, | AD, | NA |
| 3934- | RT, | Rutin: A Potential Therapeutic Agent for Alzheimer Disease |
| - | Review, | AD, | NA |
| 3932- | RT, | Rutin as a Natural Therapy for Alzheimer's Disease: Insights into its Mechanisms of Action |
| - | Review, | AD, | NA |
| 4217- | Sage, | RosA, | Aroma, | Neuroprotective Potential of Aromatic Herbs: Rosemary, Sage, and Lavender |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4114- | SAMe, | S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research |
| - | Review, | AD, | NA |
| 6064- | SeNPs, | Multifunctional selenium-doped carbon dots for modulating Alzheimer's disease related toxic ions, inhibiting amyloid aggregation and scavenging reactive oxygen species |
| - | NA, | AD, | NA |
| 6063- | SeNPs, | Large Amino Acid Mimicking Selenium-Doped Carbon Quantum Dots for Multi-Target Therapy of Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 6052- | SeNPs, | Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease |
| - | Study, | AD, | NA |
| 6060- | SeNPs, | Multifunctional Selenium Quantum Dots for the Treatment of Alzheimer's Disease by Reducing Aβ-Neurotoxicity and Oxidative Stress and Alleviate Neuroinflammation |
| - | Study, | AD, | NA |
| 6059- | SeNPs, | Multifunctional Selenium Nanoparticles with Different Surface Modifications Ameliorate Neuroinflammation through the Gut Microbiota-NLRP3 Inflammasome-Brain Axis in APP/PS1 Mice |
| - | in-vivo, | AD, | NA |
| - | Review, | AD, | NA |
| 6057- | SeNPs, | Dual-functional selenium nanoparticles bind to and inhibit amyloid β fiber formation in Alzheimer's disease |
| - | in-vitro, | AD, | PC12 |
| 6053- | SeNPs, | CUR, | A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 6048- | SeNPs, | Unravelling the in vitro and in vivo potential of selenium nanoparticles in Alzheimer's disease: A bioanalytical review |
| - | Review, | AD, | NA |
| 6046- | SeNPs, | CGA, | Anti-amyloidogenic properties of 5‑caffeoylquinic acid-capped selenium nanoparticles |
| - | Study, | AD, | NA |
| 6044- | SeNPs, | Chit, | CGA, | Ability of selenium species to inhibit metal-induced Aβ aggregation involved in the development of Alzheimer's disease |
| - | Study, | AD, | NA |
| 4608- | SeNPs, | Selenium Nanoparticles for Biomedical Applications: From Development and Characterization to Therapeutics |
| - | Review, | Var, | NA | - | NA, | AD, | NA |
| 4190- | Sesame, | Sesame Seeds: A Nutrient-Rich Superfood |
| - | Review, | NA, | NA |
| 3663- | SFN, | Efficacy of Sulforaphane in Neurodegenerative Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3664- | SFN, | Sulforaphane Upregulates the Heat Shock Protein Co-Chaperone CHIP and Clears Amyloid-β and Tau in a Mouse Model of Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3662- | SFN, | Sulforaphane Inhibits the Generation of Amyloid-β Oligomer and Promotes Spatial Learning and Memory in Alzheimer's Disease (PS1V97L) Transgenic Mice |
| - | in-vivo, | AD, | NA |
| 3661- | SFN, | Beneficial Effects of Sulforaphane Treatment in Alzheimer's Disease May Be Mediated through Reduced HDAC1/3 and Increased P75NTR Expression |
| - | in-vitro, | AD, | NA |
| 3658- | SFN, | Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease |
| - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1333 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid